|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
TRIANGULAR MOVING AVERAGE
Trading: SELL @ $46.58
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Ra Pharmaceuticals Inc (NASDAQ:RARX) currently has a confirmed downtrend. Recent trading has caused the TMA 15 day average to move below the closing price confirming the short term trend following indicator. Currently, the return on TMA15 is -0.2%.
A triangular moving average can be calculated using various input data such as prices volume or another technical indicator.
Calculation: Triangular Moving Average (TMA):
1) SMA: n period sum / n;
2) TMA = (n SMA period sum) / N;
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|INO Inovio Pharma||4.36||9.3||34,675,337||0.5||BULLISH|
|VIVO Meridian Bioscience||8.16||9.2||1,886,706||12.9||BULLISH|
|STAA Staar Surgical||31.05||8||1,662,302||4.3||BULLISH|
|HSII Heidrick & Struggles||22.2||3.8||207,252||4||BULLISH|
|CLDX Celldex Therapeutics||2.71||3.8||455,237||9.2||BULLISH|
|EZPW Ezcorp Inc||4.79||2.4||1,002,907||1.2||BULLISH|
|WIRE Encore Wire||50.87||2.3||196,575||86.7||BULLISH|
|SBLK Star Bulk Carriers||8.18||2.1||545,828||3||BULLISH|